AstraZeneca PLC (AZN)vsUnicycive Therapeutics Inc (UNCY)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
UNCY
Unicycive Therapeutics Inc
$7.66
+6.98%
HEALTHCARE · Cap: $180.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
UNCY
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for UNCY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : UNCY
The strongest argument for UNCY centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : UNCY
The primary concerns for UNCY are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
UNCY carries more volatility with a beta of 1.80 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 19/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Unicycive Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to innovating treatments for kidney diseases, with a particular emphasis on addressing hyperphosphatemia. The company is advancing its proprietary therapies aimed at regulating phosphorus levels, which are pivotal in the management of kidney-related disorders. With a robust pipeline supported by a commitment to research and development, along with strategic partnerships to enhance its capabilities, Unicycive is well-positioned to drive significant advancements in nephrology. As its clinical trials progress, Unicycive presents a promising investment opportunity for institutional investors seeking exposure to transformative healthcare solutions.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?